Oxacarbazepine

Amber-G

Brand Name(s):Trileptal

Indication:Anticonvulsant

Rationale:

Considered:Apr-07

Review Date:Nov-22

Comments:
Drug Safety Update
Antiepileptic drugs: updated advice on switching between different manufacturers’ products
Nov 2017
…………………………
MHRA GUIDANCE issued Nov 13 available at:http://www.mhra.gov.uk/safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-A-F/Antiepilepticschangingproducts/index.htm
…………………………
The risk of serious skin-related adverse drug reactions, including Stevens-Johnson syndrome, occurring with carbamazepine may be increased in the presence of the HLA-A*3101 allele in patients of European descent or Japanese origin. However, there are currently insufficient data to support screening for this allele before starting carbamazepine treatment. Patients of European descent or Japanese origin who are known to be positive for this allele should only receive carbamazepine, oxcarbazepine or eslicarbazepine after careful consideration of the benefits and risks.

MHRA Drug Safety Advice December 2012

The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Issued: January 2012 NICE clinical guideline 137 –
http://guidance.nice.org.uk/CG137/NICEGuidance/pdf/English